Detection of BCR-ABL fusion proteins in patients with leukemia using a cytometric bead array

Leukemia and Lymphoma

Volumn 53, Issue 3, 2012, Pages 451-455

  Yujie, Wu ^a   Yu, Zhu ^a   Sixuan, Qian ^a   Li, Wang ^a   Peng, Liu ^a   Zeng, Ge ^a   Sujiang, Zhang ^a   Jianyong, Li ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

BCR ABL fusion proteins; Cytometric bead array; Leukemia

Indexed keywords

ABELSON KINASE; BREAKPOINT CLUSTER REGION PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN ABELSON KINASE FUSION PROTEIN; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CYTOMETRIC BEAD ARRAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MICROARRAY; REAL TIME POLYMERASE CHAIN REACTION; ROOM TEMPERATURE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, IMMOBILIZED; BONE MARROW CELLS; EARLY DIAGNOSIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTES; MALE; MICROSPHERES; MIDDLE AGED; MONOCYTES; POLYCYTHEMIA VERA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REAL-TIME POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; THROMBOCYTHEMIA, ESSENTIAL; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84863161784     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.625100     Document Type: Article

References (14)

1. Melo JV. Th e diversity of BCR-ABL Fusion proteins and their relationship to leukemia phenotype. Blood 1996;28:2375-2384. (Pubitemid 26327486)
2. H askovec C, Ponzetto C, Polak J., et al. P230 BCR/ABL protein may be associated with an acute leukaemia phenotype. Brit J Haematol 1998;103:1104-1108. (Pubitemid 29012651)
3. B oeckx N, Jansen MW, Haskovec C., et al. Identifi cation of e19a2 BCR-ABL fusions (mu-BCR breakpoints) at the DNA level by ligationmediated PCR. Leukemia 2005;19:1292-1295. (Pubitemid 40946025)
4. Shaff er LG, Slovak ML, Campbell LJ. ISCN (2009): International System of Human Cytogenetic Nomenclature. Basel: S Karger AG; 2009.
5. Goldman JM. Advances in CML. Clin Adv Hematol Oncol 2007; 5:270-292.
6. D ruker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112:4808-4817.
7. Ottmann OG, Druker BJ, Sawyers CL., et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acutelymphoid leukemias. Blood 2002; 100:1965-1971. (Pubitemid 35001224)
8. Guilhot F, Apperley J, Kim DW., et al. Dasatinib induces signifi cant hematologic and cytogenetic responses in patients with imatinib resistant or intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143-4150. (Pubitemid 46743375)
9. Weerkamp F, Dekking E, Ng YY., et al. Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. Leukemia 2009;23:1106-1117.
10. Raponi S, De Propris MS, Wai H., et al. An accurate and rapid fl ow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia. Haematologica 2009;94:1767-1770.
11. Xu W, Li JY, Pan JL., et al. Interphase fl u orescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia. Int J Hematol 2007;85:430-436. (Pubitemid 47457455)
12. Yu-jie Wu, Yu Zhu, Si-xuan Qian., et al. Standardization and quality control studies of ' real-time ' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-2357.
13. P rimo D, Sanchez ML, Espinosa AB., et al. Lineage involvement in chronic myeloid leukaemia: comparison between MBCR/ABL and mBCR/ABL cases. Brit J Haematol 2006;132:736-739. (Pubitemid 43381634)
14. H amilton A, Elrick L, Myssina S., et al. BCR-ABL activity and its response to drugs can be determined in CD34- CML stem cells by CrkL phosphorylation status using fl ow cytometry. Leukemia 2006;20:1035-1039. (Pubitemid 43797294)